Literature DB >> 15541412

Postcoital testing after the use of a bio-adhesive acid buffering gel (ACIDFORM) and a 2% nonoxynol-9 product.

Eliana Amaral1, Antero Perdigão, Maria Helena Souza, Christine Mauck, Donald Waller, Lourens Zaneveld, Anibal Faúndes.   

Abstract

ACIDFORM is a gel already shown to be safe in vaginal use during six consecutive days through colposcopic observation. A randomized, blinded, crossover study was carried out to compare the spermicidal effect of ACIDFORM to that of a commercial 2% nonoxynol-9 (N-9) product. Twenty sexually active, sterilized women, aged 19-45 years, with regular cycles, normal gynecological exam, no previous sexually transmitted infection (STI) and stable partner willing to undergo four postcoital tests (PCTs) at midcycle during four different menstrual cycles, were enrolled in the study. Known allergy to N-9 or ACIDFORM, oligospermic partner, chronic diseases, use of hormones, previous treatment for STI or presence of STI at screening tests were criteria for exclusion. ACIDFORM or N-9 product administered 0-30 min precoitus or ACIDFORM given 8-10 h precoitus significantly reduced the mean number of progressively motile sperm compared to control cycles (0.19, 0.07, 0.75 vs. 17.94, respectively, p<.05, Wilcoxon test). All treated cycles had five or fewer progressively motile sperm in midcycle cervical mucus, confirming in vivo the spermicidal effect of ACIDFORM previously observed in vitro and in animal models.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15541412     DOI: 10.1016/j.contraception.2004.06.007

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  11 in total

1.  Surrogate post-coital testing for contraceptive efficacy against human sperm activity in the ovine vaginal model†.

Authors:  Yong Zhu; Jamal Saada; Shrestha Bhawana; Sam Lai; Paula Villarreal; Richard Pyles; Massoud Motamedi; Gracie Vargas; Tom Moench; Kathleen L Vincent
Journal:  Biol Reprod       Date:  2021-02-11       Impact factor: 4.285

Review 2.  Mechanisms of action of currently available woman-controlled, vaginally administered, non-hormonal contraceptive products.

Authors:  B Todd Chappell; Brooke L Griffin; Brandon Howard
Journal:  Ther Adv Reprod Health       Date:  2022-07-07

3.  A novel vaginal pH regulator: results from the phase 3 AMPOWER contraception clinical trial.

Authors:  Michael A Thomas; B Todd Chappell; Bassem Maximos; Kelly R Culwell; Clint Dart; Brandon Howard
Journal:  Contracept X       Date:  2020-07-01

Review 4.  A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections.

Authors:  Valence M K Ndesendo; Viness Pillay; Yahya E Choonara; Eckhart Buchmann; David N Bayever; Leith C R Meyer
Journal:  AAPS PharmSciTech       Date:  2008-04-02       Impact factor: 3.246

5.  Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive.

Authors:  Marla J Keller; Colleen A Carpenter; Yungtai Lo; Mark H Einstein; Congzhou Liu; David N Fredricks; Betsy C Herold
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

Review 6.  Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies.

Authors:  Andrea Ries Thurman; Meredith R Clark; Gustavo F Doncel
Journal:  Infect Dis Obstet Gynecol       Date:  2011-08-09

7.  Development and In-vitro Evaluation of a Contraceptive Vagino-Adhesive Propranolol Hydrochloride Gel.

Authors:  Elahe Tasdighi; Zahra Jafari Azar; Seyed Alireza Mortazavi
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

Review 8.  Engineering monoclonal antibody-based contraception and multipurpose prevention technologies†.

Authors:  Deborah J Anderson; Joseph A Politch; Richard A Cone; Larry Zeitlin; Samuel K Lai; Philip J Santangelo; Thomas R Moench; Kevin J Whaley
Journal:  Biol Reprod       Date:  2020-08-04       Impact factor: 4.161

9.  Functional proteomic profiling reveals KLK13 and TMPRSS11D as active proteases in the lower female reproductive tract.

Authors:  Carla M J Muytjens; Yijing Yu; Eleftherios P Diamandis
Journal:  F1000Res       Date:  2018-10-19

10.  The postcoital test in the development of new vaginal contraceptives†.

Authors:  Christine K Mauck; Kathleen L Vincent
Journal:  Biol Reprod       Date:  2020-08-04       Impact factor: 4.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.